Table 3. Efficiency and Potency of Further Characterized Piperine Derivatives and Piperinea.
compd | IGABA-max (%) | EC50 (μM) | nH | n |
---|---|---|---|---|
piperine | 302 ± 27 | 52.4 ± 9.3 | 1.5 ± 0.2 | 3 |
22 | 1581 ± 74** | 86.7 ± 13.9 | 2.3 ± 0.2 | 6 |
23 | 1673 ± 146** | 51.7 ± 9.5 | 3.1 ± 0.8 | 6 |
25 | 760 ± 47** | 13.8 ± 1.8** | 1.8 ± 0.1 | 6 |
35 | 733 ± 60** | 67.7 ± 11.0 | 1.9 ± 0.3 | 6 |
43 | 505 ± 24** | 23.1 ± 3.3* | 1.6 ± 0.2 | 6 |
47 | 603 ± 87* | 70.8 ± 21.1 | 1.2 ± 0.2 | 3 |
53 | 388 ± 64 | 55.3 ± 17.6 | 1.5 ± 0.2 | 3 |
56 | 165 ± 4** | 36.8 ± 2.0 | 1.2 ± 0.0 | 3 |
72 | 706 ± 58** | 102.0 ± 11.2 | 1.9 ± 0.2 | 5 |
73 | 480 ± 85 | 31.8 ± 5.3 | 2.7 ± 0.2 | 6 |
From ref (31), including number of experiments n. Asterisks indicate significant differences from piperine: *p < 0.05; **p < 0.01.